Nuo Therapeutics Inc  

(Public, OTCMKTS:NUOT)   Watch this stock  
Find more results for OTC:CMXI
+0.0001 (0.19%)
Delayed:   9:43AM EDT
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.05 - 0.05
52 week 0.03 - 0.47
Open 0.05
Vol / Avg. 5,000.00/491,993.00
Mkt cap 6.55M
P/E 5.25
Div/yield     -
EPS 0.01
Shares 125.68M
Beta -0.75
Inst. own 0%
Nov 11, 2015
Q3 2015 Nuo Therapeutics Inc Earnings Release (Estimated) Add to calendar
Aug 14, 2015
Q2 2015 Nuo Therapeutics Inc Earnings Call
Aug 13, 2015
Q2 2015 Nuo Therapeutics Inc Earnings Release

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -30.06% -243.28%
Operating margin -153.25% -301.35%
EBITD margin - -229.69%
Return on average assets -7.04% -36.85%
Return on average equity -17.39% -88.28%
Employees 46 -
CDP Score - -


207a Perry Pkwy Ste 1
United States - Map
+1-240-4992680 (Phone)
+1-240-4992690 (Fax)

Website links


Nuo Therapeutics, Inc., (Nuo Therapeutics) formerly Cytomedix, Inc. is a biomedical company. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company pioneers biodynamic therapies within the emerging opportunities of a changing healthcare landscape. Nuo Therapeutics' flagship product, Aurix, is a biodynamic hematogel that uses a patient's own platelets and plasma as a catalyst for healing. It is the only therapy that is FDA-cleared for use on ulcers and wounds of all types. Its commercial offerings consist of point of care technologies for the safe and efficient separation of autologous blood and bone marrow to produce platelet based therapies or cell concentrates. It has two distinct platelet rich plasma (PRP) devices, the AutoloGel TM System (relaunched as Aurix in October 2014) for wound care and the Angel concentrated Platelet Rich Plasma (cPRP) System for orthopedics markets.

Officers and directors

Joseph Del Guercio Acting Chairman of the Board
Age: 43
Dean Tozer President, Chief Executive Officer, Director
Age: 48
David Emerson Jorden CPA Acting Chief Financial Officer, Director
Age: 52
Peter A. Clausen Ph.D. Chief Science Officer
Age: 49
Lyle A. Hohnke Ph.D. Independent Director
Age: 72
Stephen N. Keith M.D. Independent Director
Age: 62
Mark T. McLoughlin Independent Director
Age: 59
C. Eric Winzer Independent Director
Age: 58